Slide 1: Bruker Corporation (BRKR) Overview
Bruker Corporation (BRKR) Overview Company Presentation June 17, 2009 Frank Laukien, President & CEO Bill Knight, CFO Frank Burgaezy, Co-President Bruker AXS Stacey Desrochers, Treasurer & IR Director
Slide 2: Safe Harbor Statement
Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are
Slide 3: Breakdown of 2008 Revenue
Breakdown of 2008 Revenue Bruker can weather a severe recession and may benefit substantially from US & global stimulus programs Revenue by Customers Revenue by Geography 2008 Annual Revenue: $1.1 Billion Stimulus funding and supplementary budgets can cushion recession and may provide significant up
Slide 4: U.S. & Global Stimulus Funding for Scientific Instruments
U.S. & Global Stimulus Funding for Scientific Instruments: All U.S. government stimulus could positively affect >10% of Bruker’s revenues Global government stimulus could positively affect >20% of Bruker’s revenues Magnitude of Stimulus Effect on Bruker is difficult to estimate at this time. Anticip
Slide 5: Example of Supplementary Budget Benefit: Japan National Police Agency
Example of Supplementary Budget Benefit : Japan National Police Agency (NPA) Order for 51 Mass Spectrometers for Forensics In late 2008, the Japanese National Police Agency (NPA) signed a $12M contract (from supplementary budget) for 51 Bruker ESI-TOF mass spectrometers for: Exact Mass Analysis and
Slide 6: Key Financials: Growth, Margins & Cash Flow
Key Financials Growth, Margins & Cash Flow BRKR 2008A Financials: Revenue $1.1B ($1.03B in 2007) 7% GAAP growth (3% FX-adjusted) Adj. EBITDA $170M ($196M in 2007) Non-GAAP EPS $0.47 ($0.66 in 2007) Operating Cash Flow $107M ($108M in 2007) 12/31/08: Net Debt $56.1M (Goodwill & Intangibles)/Asset Rat
Slide 7: Strategy and Margin Opportunities of Scientific Instruments Business
Strategy and Margin Opportunities of Bruker’s Scientific Instruments Business (incl. BAXS, BBIO, BDAL and BOPT divisions) Bruker BioSpin and Bruker Optics are two fully established, market-leading and fairly profitable Bruker divisions. They strive for incremental margin improvements, operational ex
Slide 8: Bruker Advanced Supercon (BASC) Division
Bruker Advanced Supercon (BASC) Division: LTS and HTS Superconductors, Supercon Devices and Advanced Technology for Energy Applications March 2009: Bruker and Nexans Successfully Complete EU HTS Superconducting Cable Bruker is developing more efficient, flexible and reliable energy technologies Euro
Slide 9: BASC Division Financials and Comparable Companies
BASC Division Financials: 2008A revenue: $43.5M ($10.5M inter-company, $33M third-party) 2008A operating loss: ($7.6M) 2009 expected pro forma revenue (incl. Accel acquisition for entire year 2009): $71M Bruker Advanced Supercon (BASC) Division: LTS and HTS Superconductors, Supercon Devices and Adva
Slide 10: Key Financials: Important Balance Sheet Ratios
Key Financials Important Balance Sheet Ratios Operational Excellence & Lean Initiatives $0.13 change from 2006 to 2009 equates to $140M of lower working capital to support revenue run-rate WC = (A/R + Inventory)-AP 89 75 68 65 56 52 49 56 47-10 20 30 40 50 60 70 80 90 Q107 Q207 Q307 Q407 Q108 Q208 Q
Slide 11: Quantum Jumps in Performance: X-ray Revolution
Quantum Jumps in Performance X-ray Revolution: Unique, High-Performance Systems for Broader Markets and New Users 2008 PITTCON Editor’s Gold and R&D 100 Award Winner SMART X2S World’s First Fully Automated Molecular Structure Machine New: Pittcon 2009 S8 LION Simultaneous WD-XRF Spectrometer for Qua
Slide 12: Bruker BioSpin's Leadership in NMR Spectroscopy
12 Quantum Jumps in Performance Bruker BioSpin’s Global Technology and Market Leadership in NMR Spectroscopy November 2008: Saudi KAUST order of 10 NMR systems for ~$20M (revenue not recognized yet) 3 New Unique Ultra-High Field NMR Magnet Introductions in 2009 ENC ’09: world’s highest field, active
Slide 13: World's First Solid State DNP-NMR Spectrometer
Quantum Jumps in Performance World’s First Solid State DNP-NMR Spectrometer with >50x Signal Enhancement Factor! World’s first Commercial solid state Dynamic Nuclear Polarization (DNP)-NMR spectrometer, co-developed with MIT Polarization enhancement yields factor 50-150x gain in sensitivity for Soli
Slide 14: Revolution in Mass Spectrometry: maXis UHR-TOF
Quantum Jumps in Performance Revolution in Mass Spectrometry maXis™ UHR-TOF launched at ASMS 2008 Bruker has ‘rewritten the book’ with UHR-TOF Ultra-high resolution 40-60k Broad mass range and high mass Mass accuracy in MS & MS/MS <1ppm High speed at 20 full spectra/sec Isotopic fidelity for molecul
Slide 15: MALDI-TOF MS Based Edmass Solution
Pittcon/ASMS 2009: New Opportunities: MALDI-TOF MS Based Edmass™ Solution Next-Gen Protein Sequencing! MALDI In-Source-Decay Mass Spectrometry A single Edmass™ spectrum can provide for sequence calls of >80 a.a. residues in seconds Both N- and C-terminals can be assigned using T3-sequencing on Bruke
Slide 16: Bruker MALDI Molecular Imager
ASMS 2009: New Opportunities Bruker MALDI Molecular Imager™ MALDI Tissue Imaging and Molecular Histology Complete MALDI Molecular Imaging Solution: For proteins, peptides, lipids based on MALDI-TOF New: FTMS Imaging of drugs and metabolites New: Molecular Histology by MIRAX integration ImagePrep™ Sa
Slide 17: New ultrafleXtreme MALDI-TOF/TOF
ASMS 2009: Quantum Jumps in Performance Revolution in Mass Spectrometry Continues New ultrafleXtremeTM MALDI-TOF/TOF New ultrafleXtreme™ is Fastest and Most Flexible MALDI-TOF/TOF 1 kHz proprietary smartbeam™-II laser True 1 kHz in TOF and TOF/TOF Highly complementary to ESI-MS maXis, ion traps or F
Slide 18: New amaZon Ion Trap & solariX FTMS
ASMS 2009: Quantum Jumps in Performance Revolution in Mass Spectrometry Continues New amaZon Ultra-Sensitive Ion Trap & solariX FTMS amaZon™ Redefines Ion Trap Mass Spec Dual ion funnel transfer into ion trap, delivering 10-fold jump in sensitivity Unrivalled scan speed of 52,000 u/sec at 0.58u reso
Slide 19: Bruker Corporation
><) BRUKER C™) Bruker Corporation
Slide 20: Growth and Margins GAAP Reconciliation: Net Income
Growth and Margins GAAP Reconciliation We believe the inclusion of the non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such
Slide 21: Growth and Margins GAAP Reconciliation: EPS
Growth and Margins GAAP Reconciliation We believe the inclusion of the non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such
Slide 22: Growth and Margins GAAP Reconciliation: EBITDA
Growth and Margins GAAP Reconciliation We believe the inclusion of the non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such
Slide 23: Growth and Margins GAAP Reconciliation: Notes
Growth and Margins GAAP Reconciliation “GAAP” (Reported) results were determined in accordance with United States Generally Accepted Accounting Principles (GAAP). Results in 2008 and 2007 include charges associated with the acquisition of the Bruker Biospin Group. Under US GAAP, this transaction was